Bristol's Pravachol for prevention of coronary artery disease is cost-effective -- USC analysis.
Executive Summary
BRISTOL PRAVACHOL MONOTHERAPY IS COST-EFFECTIVE FOR CAD PREVENTION, University of Southern California School of Pharmacy Professor Joel Hay, PhD, reported at IIR's formulary development conference Feb. 26 in Coronado, Calif. "Pravastatin monotherapy in secondary prevention of coronary artery disease is cost-effective," Hay concluded based on a re-analysis of a pair of pravastatin clinical studies.